Cargando…
Telmisartan in the diabetic murine model of acute myocardial infarction: dual contrast manganese-enhanced and delayed enhancement MRI evaluation of the peri-infarct region
BACKGROUND: A novel MRI technique, employing dual contrast manganese-enhanced MRI (MEMRI) and delayed enhancement MRI (DEMRI), can evaluate the physiologically unstable peri-infarct region. Dual contrast MEMRI–DEMRI enables comprehensive evaluation of telmisartan to salvage the peri-infarct injury t...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743104/ https://www.ncbi.nlm.nih.gov/pubmed/26846539 http://dx.doi.org/10.1186/s12933-016-0348-y |
_version_ | 1782414297621594112 |
---|---|
author | Toma, Ildiko Kim, Paul J. Dash, Rajesh McConnell, Michael V. Nishimura, Dwight Harnish, Phillip Yang, Phillip C. |
author_facet | Toma, Ildiko Kim, Paul J. Dash, Rajesh McConnell, Michael V. Nishimura, Dwight Harnish, Phillip Yang, Phillip C. |
author_sort | Toma, Ildiko |
collection | PubMed |
description | BACKGROUND: A novel MRI technique, employing dual contrast manganese-enhanced MRI (MEMRI) and delayed enhancement MRI (DEMRI), can evaluate the physiologically unstable peri-infarct region. Dual contrast MEMRI–DEMRI enables comprehensive evaluation of telmisartan to salvage the peri-infarct injury to elucidate the underlying mechanism of restoring the ischemic cardiomyopathy in the diabetic mouse model. METHODS AND RESULTS: Dual contrast MEMRI–DEMRI was performed on weeks 1, 2, and 4 following initiation of telmisartan treatment in 24 left anterior descendent artery ligated diabetic mice. The MRI images were analyzed for core infarct, peri-infarct, left ventricular end-diastolic, end-systolic volumes, and the left ventricular ejection fraction (LVEF). Transmission electron microscopy (TEM) and real-time PCR were used for ex vivo analysis of the myocardium. Telmisartan vs. control groups demonstrated significantly improved LVEF at weeks 1, 2, and 4, respectively (33 ± 7 %*** vs. 19 ± 5 %, 29 ± 3 %*** vs. 22 ± 4 %, and 31 ± 2 %*** vs 18 ± 6 %, ***p < 0.001). The control group demonstrated significant differences in the scar volume measured by MEMRI and DEMRI, demonstrating peri-infarct injury. Telmisartan group significantly salvaged the peri-infarct injury. The myocardial effects were validated by TEM, which confirmed the presence of the injured but viable cardiomyocyte morphology in the peri-infarct region and by flow cytometry of venous blood, which demonstrated significantly increased circulating endothelial progenitor cells (EPCs). CONCLUSION: The improved cardiac function in ischemic cardiomyopathy of diabetic mice by telmisartan is attributed to the attenuation of the peri-infarct injury by the angiogenic effects of EPCs to salvage the injured cardiomyocytes. Dual-contrast MEMRI–DEMRI technique tracked the therapeutic effects of telmisartan on the injured myocardium longitudinally. |
format | Online Article Text |
id | pubmed-4743104 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-47431042016-02-06 Telmisartan in the diabetic murine model of acute myocardial infarction: dual contrast manganese-enhanced and delayed enhancement MRI evaluation of the peri-infarct region Toma, Ildiko Kim, Paul J. Dash, Rajesh McConnell, Michael V. Nishimura, Dwight Harnish, Phillip Yang, Phillip C. Cardiovasc Diabetol Original Investigation BACKGROUND: A novel MRI technique, employing dual contrast manganese-enhanced MRI (MEMRI) and delayed enhancement MRI (DEMRI), can evaluate the physiologically unstable peri-infarct region. Dual contrast MEMRI–DEMRI enables comprehensive evaluation of telmisartan to salvage the peri-infarct injury to elucidate the underlying mechanism of restoring the ischemic cardiomyopathy in the diabetic mouse model. METHODS AND RESULTS: Dual contrast MEMRI–DEMRI was performed on weeks 1, 2, and 4 following initiation of telmisartan treatment in 24 left anterior descendent artery ligated diabetic mice. The MRI images were analyzed for core infarct, peri-infarct, left ventricular end-diastolic, end-systolic volumes, and the left ventricular ejection fraction (LVEF). Transmission electron microscopy (TEM) and real-time PCR were used for ex vivo analysis of the myocardium. Telmisartan vs. control groups demonstrated significantly improved LVEF at weeks 1, 2, and 4, respectively (33 ± 7 %*** vs. 19 ± 5 %, 29 ± 3 %*** vs. 22 ± 4 %, and 31 ± 2 %*** vs 18 ± 6 %, ***p < 0.001). The control group demonstrated significant differences in the scar volume measured by MEMRI and DEMRI, demonstrating peri-infarct injury. Telmisartan group significantly salvaged the peri-infarct injury. The myocardial effects were validated by TEM, which confirmed the presence of the injured but viable cardiomyocyte morphology in the peri-infarct region and by flow cytometry of venous blood, which demonstrated significantly increased circulating endothelial progenitor cells (EPCs). CONCLUSION: The improved cardiac function in ischemic cardiomyopathy of diabetic mice by telmisartan is attributed to the attenuation of the peri-infarct injury by the angiogenic effects of EPCs to salvage the injured cardiomyocytes. Dual-contrast MEMRI–DEMRI technique tracked the therapeutic effects of telmisartan on the injured myocardium longitudinally. BioMed Central 2016-02-05 /pmc/articles/PMC4743104/ /pubmed/26846539 http://dx.doi.org/10.1186/s12933-016-0348-y Text en © Toma et al. 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Original Investigation Toma, Ildiko Kim, Paul J. Dash, Rajesh McConnell, Michael V. Nishimura, Dwight Harnish, Phillip Yang, Phillip C. Telmisartan in the diabetic murine model of acute myocardial infarction: dual contrast manganese-enhanced and delayed enhancement MRI evaluation of the peri-infarct region |
title | Telmisartan in the diabetic murine model of acute myocardial infarction: dual contrast manganese-enhanced and delayed enhancement MRI evaluation of the peri-infarct region |
title_full | Telmisartan in the diabetic murine model of acute myocardial infarction: dual contrast manganese-enhanced and delayed enhancement MRI evaluation of the peri-infarct region |
title_fullStr | Telmisartan in the diabetic murine model of acute myocardial infarction: dual contrast manganese-enhanced and delayed enhancement MRI evaluation of the peri-infarct region |
title_full_unstemmed | Telmisartan in the diabetic murine model of acute myocardial infarction: dual contrast manganese-enhanced and delayed enhancement MRI evaluation of the peri-infarct region |
title_short | Telmisartan in the diabetic murine model of acute myocardial infarction: dual contrast manganese-enhanced and delayed enhancement MRI evaluation of the peri-infarct region |
title_sort | telmisartan in the diabetic murine model of acute myocardial infarction: dual contrast manganese-enhanced and delayed enhancement mri evaluation of the peri-infarct region |
topic | Original Investigation |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4743104/ https://www.ncbi.nlm.nih.gov/pubmed/26846539 http://dx.doi.org/10.1186/s12933-016-0348-y |
work_keys_str_mv | AT tomaildiko telmisartaninthediabeticmurinemodelofacutemyocardialinfarctiondualcontrastmanganeseenhancedanddelayedenhancementmrievaluationoftheperiinfarctregion AT kimpaulj telmisartaninthediabeticmurinemodelofacutemyocardialinfarctiondualcontrastmanganeseenhancedanddelayedenhancementmrievaluationoftheperiinfarctregion AT dashrajesh telmisartaninthediabeticmurinemodelofacutemyocardialinfarctiondualcontrastmanganeseenhancedanddelayedenhancementmrievaluationoftheperiinfarctregion AT mcconnellmichaelv telmisartaninthediabeticmurinemodelofacutemyocardialinfarctiondualcontrastmanganeseenhancedanddelayedenhancementmrievaluationoftheperiinfarctregion AT nishimuradwight telmisartaninthediabeticmurinemodelofacutemyocardialinfarctiondualcontrastmanganeseenhancedanddelayedenhancementmrievaluationoftheperiinfarctregion AT harnishphillip telmisartaninthediabeticmurinemodelofacutemyocardialinfarctiondualcontrastmanganeseenhancedanddelayedenhancementmrievaluationoftheperiinfarctregion AT yangphillipc telmisartaninthediabeticmurinemodelofacutemyocardialinfarctiondualcontrastmanganeseenhancedanddelayedenhancementmrievaluationoftheperiinfarctregion |